Medethix Incorporated Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: Medethix Incorporated Pharmaceutical Import Records from India — 2 Products, $289.3K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medethix Incorporated — Pharmaceutical Importer Profile (2026) | 2 Products, $289.3K Trade | TransData Nexus

Medethix Incorporated

Pharmaceutical Importer · Philippines · Respiratory Focus · $289.3K Total Trade · DGFT Verified

Medethix Incorporated is a pharmaceutical importer based in Philippines with a total trade value of $289.3K across 2 products in 2 therapeutic categories. Based on 9 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Medethix Incorporated sources from 10 verified Indian suppliers, with Albert David Limited accounting for 55.0% of imports.

Medethix Incorporated — Import Portfolio & Supplier Network

Medethix Incorporated import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Medethix Incorporated?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Albert David Limited	$1.0M	43	55.0%
Concept Pharmaceuticals Limited	$244.2K	10	13.1%
Khandelwal Laboratories Private Limited	$183.1K	24

What Formulations Does Medethix Incorporated Import?

Formulation	Value	Ships
Tablets of tramadol hcl37.5	$50.0K	3
Medicaments lupibile (ursodeoxycholic	$50.0K	1
Lupibile ursodeoxycholic acid 300 MG TAB drug lic dl46mb valid 31 12 2027 batch no 3t76003 mfg 02 2023 exp 01	$50.0K	1
Lupibile ursodeoxycholic acid 300 MG TAB drug lic dl46mb valid 31 12 2027 batch no 3t76002 mfg 02 2023 exp 01	$50.0K	1
Dydrogest(dydrogesterone 10MG	$50.0K	1
Lupibile ursodeoxycholic acid 300 MG	$50.0K	1
Lupibile (ursodeoxycholic acid 300 MG TAB) drug lic-dl46mb valid 31.12.2027 (batch no-3t76005 mfg.08/2023 exp.07/2026)	$50.0K	1
Lupibile ursodeoxycholic acid 300 MG TAB drug lic-dl46mb valid 31.12.2027 batch no-3t76006 manufacturing .09/2023	$50.0K	1
Lupibile (ursodeoxycholic acid 300 MG TAB) drug lic-dl46mb valid 31.12.2027 (batch no-3t76009 mfg.12/2023 exp.11/2026)	$50.0K	1
Ursodeoxycholic acid 300 MG tablet, packing: Box of	$50.0K	1
Lupibile (ursodeoxycholic acid 300 MG TAB) drug lic-dl46mb valid 31.12.2027 (batch no-4t76001 mfg.03/2024 exp.02/2027)	$50.0K	1
Lupibile (ursodeoxycholic acid 300 MG TAB) drug lic-dl46mb valid 31.12.2027 (batch no-4t76002 mfg.04/2024 exp.03/2027)	$50.0K	1
Ursodexycholic acid 300 MG	$50.0K	1
Pantec-dsr pantoprazole+domperidone modified release(delayed release pantoprazole sodium & domperidone sr capsules)	$47.5K	1
Pharmacuticals article / ods / product / item pantec-dsr	$43.9K	1

Medethix Incorporated imports 80 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ipratropium	Respiratory	$243.1K	5	0.4%	17
2	Plasma	Other	$46.2K	4	1.6%	9

Medethix Incorporated imports 2 pharmaceutical products across 2 categories into Philippines totaling $289.3K.

Medethix Incorporated — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

MedEthix Incorporated is a Philippine-based pharmaceutical company established in 2009, specializing in the sourcing, registration, importation, and distribution of healthcare products. Headquartered at 6/F RFM Corporate Center, Pioneer St, Mandaluyong City, 1550 Philippines, the company is committed to making quality healthcare solutions accessible and affordable to every Filipino. (medethix.com.ph)

In November 2019, MedEthix expanded its operations through a strategic partnership with Ayala Healthcare Holdings, Inc. (AC Health), a subsidiary of the Ayala Group. This collaboration aimed to strengthen the pharmaceutical supply chain in the Philippines, enhancing the availability of quality medicines across the country. (medethix.com.ph)

2Distribution Network

MedEthix's distribution network is strategically located in the National Capital Region (NCR), with warehouses situated in Pasay City. These facilities adhere to Good Warehousing Practice (GWP), ensuring consistent temperature monitoring and strict cold-chain controls to maintain product quality. The company's logistics capabilities are designed to meet international standards, facilitating efficient distribution throughout the Philippines. (medethix.com.ph)

3Industry Role

As a pharmaceutical importer and distributor, MedEthix plays a pivotal role in the Philippine pharmaceutical supply chain. The company sources high-quality branded generic medicines and healthcare commodities from international manufacturers, ensuring compliance with current Good Manufacturing Practice (GMP) standards. MedEthix's strong regulatory capabilities enable it to expeditiously acquire marketing authorizations, thereby enhancing the availability of essential medicines in the local market. (medethix.com.ph)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Medethix Incorporated

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

MedEthix's sourcing strategy exhibits a high degree of concentration, with a portfolio comprising only two imported products across two therapeutic categories. The top five products—comprising Ipratropium and Plasma—account for 100% of the company's imports. This singular focus on a limited product range suggests a strategic choice to specialize in specific therapeutic areas, potentially allowing for deeper market penetration and expertise. However, such concentration also exposes the company to risks associated with supply chain disruptions or regulatory changes affecting these products.

2Supply Chain Resilience

MedEthix's supply chain resilience is bolstered by its partnerships with multiple Indian suppliers, including ALBERT DAVID LIMITED, CONCEPT PHARMACEUTICALS LIMITED, and KHANDELWAL LABORATORIES PRIVATE LIMITED. This diversified supplier base mitigates risks associated with single-source dependency. The company's adherence to stringent regulatory standards, such as obtaining over 500 product registrations from the Philippine FDA, underscores its commitment to quality and compliance. Additionally, the strategic location of its warehouses in Pasay City facilitates efficient logistics and distribution, enhancing supply chain robustness. (medethix.com.ph)

Strategic Implications

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

The Philippine Food and Drug Administration (FDA) is the primary regulatory body overseeing pharmaceutical imports into the Philippines. Key legislation governing these imports includes the Food and Drug Administration Act of 2009 (Republic Act No. 9711), which outlines the regulatory framework for the importation, distribution, and marketing of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining product registrations from the Philippine FDA, ensuring compliance with local standards and regulations. (medethix.com.ph)

2Import Licensing & GMP

Import licensing requirements in the Philippines mandate that pharmaceutical importers obtain product registrations from the Philippine FDA, demonstrating compliance with local standards. Good Manufacturing Practice (GMP) certificates from recognized authorities, such as the World Health Organization (WHO) or the Pharmaceutical Inspection Co-operation Scheme (PIC/S), are essential for ensuring product quality and safety. Wholesale distribution authorization is also required, allowing companies like MedEthix to distribute pharmaceutical products within the country. (medethix.com.ph)

3Quality & Labeling

Medethix Incorporated — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

MedEthix's focus on respiratory products, particularly Ipratropium, indicates a strategic alignment with prevalent health concerns in the Philippines, such as respiratory diseases. The importation of Plasma suggests a commitment to providing essential healthcare solutions. This product strategy is driven by market demand for effective treatments in these therapeutic areas, positioning MedEthix to address significant health needs within the country. (medethix.com.ph)

2Sourcing Profile

MedEthix's sourcing strategy emphasizes high-quality branded generic medicines and healthcare commodities from manufacturers compliant with current Good Manufacturing Practice (GMP). The company's partnerships with international suppliers, including those from India, reflect a commitment to quality and regulatory compliance. This approach ensures that imported products meet the standards required for distribution in the Philippine market. (medethix.com.ph)

3Market Positioning

MedEthix serves the wholesale distribution segment of the Philippine pharmaceutical market, supplying high-quality branded generic medicines and healthcare commodities to various stakeholders, including pharmacies, hospitals, and clinics. The company's strategic partnerships and focus on regulatory compliance enable it to effectively meet the needs of the healthcare sector, contributing to improved access to essential medicines across the country. (medethix.com.ph)

Seller's Guide — How to Become a Supplier to Medethix Incorporated

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with MedEthix, given the company's focus on high-quality branded generic medicines and its established distribution network in the Philippines. Potential gaps in MedEthix's current sourcing include diversification into additional therapeutic areas and the introduction of new dosage forms. Indian exporters can explore these opportunities by aligning their product offerings with MedEthix's strategic focus and quality standards. (medethix.com.ph)

2Requirements & Qualifications

Indian exporters seeking to supply MedEthix and the Philippine market must ensure that their products comply with the Philippine FDA's regulatory requirements, including obtaining necessary product registrations. Manufacturers should hold GMP certificates from recognized authorities such as the WHO or PIC/S. Additionally, adherence to quality standards, including batch testing, stability requirements, and labeling in English and Filipino, is essential. (medethix.com.ph)

3How to Approach

Frequently Asked Questions — Medethix Incorporated

What products does Medethix Incorporated import from India?

Medethix Incorporated imports 2 pharmaceutical products across 2 categories. Top imports: Ipratropium ($243.1K), Plasma ($46.2K).

Who supplies pharmaceuticals to Medethix Incorporated from India?

Medethix Incorporated sources from 10 verified Indian suppliers. The primary supplier is Albert David Limited (55.0% of imports, $1.0M).

What is Medethix Incorporated's total pharmaceutical import value?

Medethix Incorporated's total pharmaceutical import value from India is $289.3K, based on 9 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Medethix Incorporated focus on?

Medethix Incorporated imports across 2 categories. The largest: Respiratory (84.0%), Other (16.0%).

Get Full Medethix Incorporated Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.